Astrazeneca hits an all-time high after its Enhertu medicine gets FDA priority review

Astrazeneca Share Price: Astrazeneca reached an all-time high of Rs 6749.95 on BSE on Wednesday (January 31, 2024) after the pharma firm's Enhertu medicine got FDA priority review.

The stock was trading higher by 6.44 per cent, or Rs 408.20, at Rs 6749.95 at 9:43 am on Wednesday.

Astrazeneca's Enhertu will be reportedly used for the treatment of adults with unresectable or metastatic HER2 positive solid tumours.

The medicine is for those pateints who have received prior treatment or who have no satisfactory alternative treatment options.

On Monday, the drugmaker also said that it had planned to import a range of critical drugs and was conducting as many as 50 clinical trials in India.  

It said it was to import Palivizumab for respiratory infections, Tremelimumab for cancer, and a Fixed Dose Combination (FDC) of Budesonide, Formoterol fumarate, Glycopyrronium for asthma combination.